Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 3ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1 yubykov@gmail.com
Список исп. литературыСкрыть список 1. Морозов П.В., Медведев В.Э. Карипразин – новый антипсихотик для лечения эндогенных психических расстройств. Психиатрия и психофармакотерапия им. П.Б.Ганнушкина. 2014; 1: 9–14. / Morozov P.V., Medvedev V.E. Cariprazin – new antipsychotic for the treatment of endogenous mental disorders. Psychiatry and Psychopharmacotherapy. [in Russian] 2. Шмуклер А.Б. Карипразин – антипсихотик с новыми уникальными потенциальными возможностями для лечения шизофрении и аффективных расстройств. Соц. и клин. психиатрия. 2014; 24 (2): 72–5. / Shmukler A.B. Kariprazin – antipsikhotik s novymi unikal'nymi potentsial'nymi vozmozhnostiami dlia lecheniia shizofrenii i affektivnykh rasstroistv. Sots. i klin. psikhiatriia. 2014; 24 (2): 72–5. [in Russian] 3. Agai-Csongor E, Domány G, Nógrádi K et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett 2012; 22 (10): 3437–40. 4. Caccia S, Invernizzi RW, Nobili A, Pasina L. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag 2013; 9: 319–28. 5. Choi YK, Adham N, Kiss B et al. Long-term effects of cariprazine exposure on dopamine receptor subtypes. CNS Spectr 2014; 19 (3): 268–77. 6. Citrome L, Durgam S, Lu K et al. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry 2016; 77 (1): 109–15. 7. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013; 9 (2): 193–206. 8. Citrome L. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist. Clin Schizophr Relat Psychoses 2016; 10 (2): 109–19. 9. Corponi F, Serretti A, Montgomery S, Fabbri C. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol 2017; 32 (6): 309–18. 10. Cutler AJ, Durgam S, Wang Y et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr 2018; 23 (1): 39–50. 11. De Deurwaerdère P. Cariprazine: New dopamine biased agonist for neuropsychiatric disorders. Drugs Today (Barc) 2016; 52 (2): 97–110. 12. Durgam S, Cutler AJ, Lu K et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry 2015; 76: e1574–e1582. 13. Durgam S, Starace A, Li D et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schiz Res 2014; 152: 450–7. 14. Durgam S, Earley W, Li R et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res 2016; 176 (2–3): 264–71. 15. Durgam S, Earley W, Lu K et al. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. Int J Clin Pract 2017; 71 (12). 16. Durgam S, Greenberg WM, Li D et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl) 2017; 234 (2): 199–209. 17. Earley W, Durgam S, Lu K et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol 2017; 32 (6): 319–28. 18. EMA. EMA Public Assessment Report on Reagila. 2017. Available at: https: //www.ema.europa.eu/documents/assessment-report/reagila-epar-public-assessment-report_en.pdf 19. Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 2017; 7 (1): 29–41. 20. Girgis RR, Slifstein M, D’Souza D et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [ (11)C]- (+)-PHNO. Psychopharmacology (Berl) 2016; 233 (19–20): 3503–12. 21. Graff-Guerrero A, Mizrahi R, Agid O et al. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]- (+)-PHNO PET study. Neuropsychopharmacology 2009; 34 (4): 1078–86. 22. Gross G, Drescher K. The role of dopamine D3 receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol 2012; 213: 167–210. 23. Gyertyán I, Kiss B, Sághy K et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 2011; 59 (6): 925–35. 24. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 2005; 10 (13): 917–25. 25. Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an International, phase III clinical trial. J Clin Psychopharmacol 2015; 35 (4): 367–73. 26. Kapás M, Mészáros GP, Yu B et al. (P.3.c.051) Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers. Eur Neuropsychopharmacol 2008; 18 (Suppl. 4): S433. 27. Kirschner N, Gémesi LI, Vastag M et al. In vitro metabolism of RGH-188; Presented at the 10th European International Society of the Study of Xenobiotics (ISSX), Meeting; May 18–21, 2008. 28. Kiss B, Horvath A, Nemethy Z et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010; 333 (1): 328–40. 29. Kiss B, Laszlovszky I, Horváth A et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 2008; 378 (5): 515–28. 30. Krause M, Zhu Y, Huhn M et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2018. 31. Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28 (3): 519–26. 32. Laszlovsky I, Németh G, Mészáros P et al. Dopamine D2/D3 receptor occupancy of RGH-188, a D3/D2 antagonist/partial agonist antipsychotic, in healthy volunteers. Eur Neuropsychopharmacol 2007; 17 (Suppl. 4): S455. 33. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382 (9896): 951–62. 34. Leung JY, Barr AM, Procyshyn RM et al. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 2012; 135 (2): 113–22. 35. McCormick PN, Kapur S, Graff-Guerrero A et al. The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology 2010; 35 (8): 1826–35. 36. Mészáros GP, Kapás M, Borsos M et al. (P.3.c.047) Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. Eur Neuropsychopharmacol 2007; 17 (Suppl. 4): S451–S452. 37. Nasrallah HA, Earley W, Cutler AJ et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry 2017; 17 (1): 305. 38. Németh G, Laszlovszky I, Czobor P et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet 2017; 389 (10074): 1103–13. 39. Németh B, Molnár A, Akehurst R et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res 2017; 6 (8): 639–48. 40. Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 2011; 17 (2): 97–103. 41. Pásztor Mészáros G, Agai-Csongor E, Kapaś M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-cariprazine in human plasma and urine. J Pharm Biomed Anal 2008; 48 (2): 388–97. 42. Potkin S, Keator D, Mukherjee J et al. Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. Eur Neuropsychopharmacol 2009; 19 (Suppl. 3): S316. 43. Reynolds GP. Histamine and antipsychotic drug-induced weight gain. J Psychopharmacol 2012; 26 (12): 1608–9. 44. Richelson E. New antipsychotic drugs: how do their receptor-binding profiles compare? J Clin Psychiatry 2010; 71 (9): 1243–4. 45. Roberts RJ, Findlay LJ, El-Mallakh PL, El-Mallakh RS. Upd ate on schizophrenia and bipolar disorder: focus on cariprazine. Neuropsychiatr Dis Treat 2016; 12: 1837–42. 46. Ruiz P. Comprehensive textbook of psychiatry 2017. 47. Scarff JR. Cariprazine for Schizophrenia and Bipolar Disorder. Innov Clin Neurosci 2016; 13 (9–10): 49–52. 48. Scarff JR. The prospects of cariprazine in the treatment of schizophrenia. Ther Adv Psychopharmacol 2017; 7 (11): 237–9. 49. Seneca N, Finnema SJ, Laszlovszky I et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl) 2011; 218 (3): 579–87. 50. Solmi M, Murru A, Pacchiarotti I et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 2017; 13: 757–77. 51. Stahl SM. Case Studies: Stahl's Essential Psychopharmacology. Cambridge University Press. 1st Ed. 2015. 52. Stahl SM. Case Studies: Stahl's Essential Psychopharmacology: Volume 2. Cambridge University Press. 1st Ed. 2017. 53. Stahl SM. Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. 6th Ed. 2016. 54. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. 4rd Ed. 2013. 55. Vraylar (cariprazine) package insert. Parsippany, New Jersey: Sep, 2015. 56. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. Psychiatr Pract 2007; 13 (1): 13–24. 57. Werner FM, Coveñas R. New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine. Ther Clin Risk Manag 2015; 11: 1657–61. 58. Zhao MJ, Qin B, Wang JB et al. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol 2018; 38 (1): 55–9. 59. Zimnisky R, Chang G, Gyertyán I, Kiss B et al. Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention se t-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 2013; 226 (1): 91–100.